22091-38-9

Basic information

• Product Name: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-
• CAS NO: 22091-38-9
• Molecular Formula: C10H7BrClNO
• Molecular Weight: 272.529
• Mol File: 22091-38-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-(22091-38-9)
• EPA Substance Registry System: Oxazole, 2-(4-bromophenyl)-4-(chloromethyl)-(22091-38-9)

Safety Data

• Hazardous Substances Data: 22091-38-9(Hazardous Substances Data)

Upstream product

• 698-67-9 p-bromobenzamide 
• 534-07-6 1,3-Dichloroacetone 
• 1122-91-4 4-bromo-benzaldehyde 
• 1239589-17-3 methyl 2-(4-bromophenyl)-1,3-oxazole-4-carboxylate 
• 36841-48-2 2-(4-bromophenyl)-4-hydroxymethyloxazole 

Downstream Products

• 22087-29-2 2-(2-(4-bromophenyl)oxazol-4-yl)acetonitrile 
• 36841-65-3 5-bromo-2-(4-bromo-3-nitro-phenyl)-4-chloromethyl-oxazole 
• 59398-95-7 5-bromo-2-(4-bromo-phenyl)-oxazole-4-carbaldehyde 
• 36841-59-5 [5-bromo-2-(4-bromo-phenyl)-oxazol-4-yl]-methanol 
• 33162-11-7 2-(4-bromo-phenyl)-4-iodomethyl-oxazole 
• 36841-48-2 2-(4-bromophenyl)-4-hydroxymethyloxazole 
• 36841-63-1 2-(4-bromo-3-nitro-phenyl)-4-chloromethyl-oxazole 
• 36841-54-0 5-bromo-2-(4-bromo-phenyl)-4-chloromethyl-oxazole 
• 55327-32-7 2-(4-bromo-phenyl)-oxazole-4-carbaldehyde 
• 33249-83-1 1-[2-(4-bromo-phenyl)-oxazol-4-ylmethyl]-1,3,5,7-tetraaza-adamantanium; chloride 
• 876617-48-0 2-(4-bromo-phenyl)-4-pyrrolidin-1-ylmethyI-oxazole 

Relevant articles and documents

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.